Celltrion Signs 299.3 Billion KRW Supply Contract for Biosimilar Antibody Drugs

[Asia Economy Reporter Junho Hwang] Celltrion announced on the 29th that it has signed a supply contract for biosimilar antibody drugs (Remsima IV, Truxima, Herzuma, Vegzelma) with its affiliate Celltrion Healthcare. The contract amount is 299.3 billion KRW, which corresponds to 15.66% of the sales in 2021. The contract period is until the 30th of this month.